This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): EHT0202, SQ-20009
Description: EHT 0202, a small molecule compound, redirects the processing of the Amyloid Precursor Protein (APP) towards the a-secretase pathway, increasing the production of soluble APP alpha (sAPPa) in vitro and in vivo at the expense of the beta amyloid peptide (Aß), a key component in the evolution of Alzheimer's disease. EHT 0202 also shows potent neuroprotective properties against Aß-associated stresses, these include oxidative stress and excitotoxicity. Finally, EHT 0202 modulates GABA A receptors and weakly inhibits PDE4 (phosphodiesterase 4).
In vivo trials showed that oral administration of EHT 0202 to aged animals restored cognition to levels similar to that of normal adult animals. EHT 0202 has also been shown to reduce scopolamine induced amnesia in rats.
Additional information available to subscribers only: